CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in two upcoming investor conferences.
Jefferies Healthcare Conference
Fireside Chat
Date: Thursday, June 8, 2023
Time: 8:30 a.m. ET
Goldman Sachs 44th Annual Global Healthcare Conference
Fireside Chat
Date: Wednesday, June 14, 2023
Time: 2:40 p.m. PT / 5:40 p.m. ET
Live webcasts of the fireside chats will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. Archived replays will be available on the same website for approximately 90 days.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.
| Last Trade: | US$0.83 |
| Daily Change: | 0.02 2.59 |
| Daily Volume: | 137,001 |
| Market Cap: | US$46.070M |
October 15, 2024 September 17, 2024 August 06, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
